New cancer drug GEN1057 tested in early trial – but study stopped early

NCT ID NCT06573294

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial tested a new antibody drug called GEN1057 in 23 people with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety and see how the drug behaves in the body. The study was terminated early, so results are limited.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED MALIGNANT SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer metastatic malignant neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Hospital Universitari Vall d'Hebron

    Barcelona, 08035, Spain

  • National Cancer Center, Tsukiji 5-1-1

    Tokyo, Japan

  • SCRI Oncology Partners

    Nashville, Tennessee, 37203, United States

  • South Texas Accelerated Research Therapeutics, LLC

    San Antonio, Texas, 78229, United States

  • Start Madrid Centro Integral Oncologico Clara Campal CIOCC

    Madrid, 28050, Spain